Loading organizations...
WaveTec Vision Systems develops ophthalmic medical devices, focusing on intraoperative wavefront technology. Its core product, the ORA System with VerifEye, delivers real-time refractive information during cataract surgery. This technology allows surgeons to precisely measure the eye and refine outcomes, enhancing lens implant accuracy for improved visual results.
Established in 1997, WaveTec Vision identified the need for immediate data during cataract procedures to enhance patient outcomes. The company was founded on the insight that real-time feedback could address variability in traditional cataract surgery. Tom Berryman served as CEO from 2005, guiding its growth in the specialized medical device sector.
The ORA System serves ophthalmic surgeons, aiding in delivering predictable refractive results. WaveTec Vision's mission focused on making advanced diagnostic capabilities accessible intraoperatively, elevating cataract surgery precision. This aimed to foster consistent and accurate patient care in ophthalmology.
WaveTec Vision has raised $11.0M across 1 funding round.
Key people at WaveTec Vision.
WaveTec Vision has raised $11.0M in total across 1 funding round.
Key people at WaveTec Vision.
WaveTec Vision has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series D in June 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2013 | $11M Series D | — | Foresite Capital | Announced |
WaveTec Vision has raised $11.0M in total across 1 funding round.
WaveTec Vision's investors include Foresite Capital.
WaveTec Vision Systems is a privately-held ophthalmic medical device company specializing in intraoperative wavefront technology for eye surgery. It develops and distributes the ORA System® with VerifEye™ (Optiwave® Refractive Analysis), a measurement tool used during cataract surgery to provide streaming refractive data, enabling surgeons to achieve better refractive outcomes for patients.[1][2] The system targets ophthalmologists and cataract patients, addressing the problem of imprecise vision correction during surgery through high-precision, real-time analysis, affordable pricing, and practice support programs.[2] While early descriptions positioned it as a developer of vision screening and laser correction systems, its core focus has solidified around the ORA technology as the proven leader in its niche.[1][2]
WaveTec Vision Systems emerged as an ophthalmologic technology innovator, with roots in developing advanced measurement systems for vision screening and laser vision correction.[1] Specific founding details are not detailed in available sources, but the company established itself as a leader in intraoperative wavefront technology, focusing on research, development, manufacturing, and distribution of the ORA System®.[2] A pivotal moment includes its recognition as the proven leader in this space, highlighted by presentations from industry executives like Thomas Frinzi, then Senior Vice President of Abbott’s vision business, underscoring its traction in cataracts, refractive surgery, and eye health.[2] Early traction likely built through proving the ORA system's precision in improving surgical outcomes for all cataract patients.[2]
WaveTec Vision Systems rides the trend of precision medicine in ophthalmology, where intraoperative tools like wavefront aberrometry address rising demand for customized cataract and refractive surgeries amid an aging global population.[2] Timing aligns with advancements in laser-assisted procedures and the push for better postoperative vision, fueled by market forces like increasing cataract prevalence and surgeon needs for data-driven decisions.[1][2] It influences the ecosystem by setting standards for intraoperative refractive analysis, enabling more equitable access to optimal outcomes and supporting integration with broader eye health portfolios, as evidenced by executive ties to major players like Abbott.[2]
WaveTec Vision Systems is poised to expand its ORA platform amid growing ophthalmic device adoption, potentially integrating AI-driven enhancements for even finer precision in surgeries. Trends like personalized refractive tech and minimally invasive procedures will shape its path, amplifying influence through partnerships or acquisitions in the $10B+ ophthalmology market. As the leader in intraoperative wavefront, its role in elevating cataract outcomes positions it for sustained growth, tying back to its core mission of transformative vision correction.[2]
